Saray Duran-Sanchon
Overview
Explore the profile of Saray Duran-Sanchon including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
350
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gomez-Matas J, Duran-Sanchon S, Lozano J, Ferrero G, Tarallo S, Pardini B, et al.
iScience
. 2024 Mar;
27(3):109283.
PMID: 38450150
Small nucleolar RNAs (snoRNAs) have been identified dysregulated in several pathologies, and these alterations can be detected in tissues and in circulation. The main aim of this study was to...
2.
Duran-Sanchon S, Herrera-Pariente C, Moreira L
Rev Esp Enferm Dig
. 2020 Jul;
112(8):642-648.
PMID: 32686445
Colorectal cancer (CRC) is one of the most frequent neoplasia in developed countries and the second leading cause of cancer death in Spain. It develops through the accumulation of genetic...
3.
Duran-Sanchon S, Moreno L, Gomez-Matas J, Auge J, Serra-Burriel M, Cuatrecasas M, et al.
Clin Gastroenterol Hepatol
. 2020 Mar;
19(2):323-330.e1.
PMID: 32113893
Background & Aims: An algorithm based on fecal levels of 2 microRNAs (miR-421 and miR-27a-3p), fecal hemoglobin concentration, and patient age and sex can identify patients with advanced colorectal neoplasia....
4.
Duran-Sanchon S, Vila-Navarro E, Marcuello M, Lozano J, Munoz J, Cubiella J, et al.
Biomolecules
. 2019 Dec;
10(1).
PMID: 31877644
Background: Circulating microRNA (miRNA) analysis is a growing research field. However, it usually requires an endogenous control or housekeeping (HK) in order to normalize expression of specific miRNAs throughout different...
5.
Duran-Sanchon S, Moreno L, Auge J, Serra-Burriel M, Cuatrecasas M, Moreira L, et al.
Gastroenterology
. 2019 Oct;
158(4):947-957.e4.
PMID: 31622624
Background & Aims: Screening for colorectal cancer (CRC) is effective in the population at average risk. The most extended strategy in organized programs involves the fecal immunochemical test, which is...
6.
Marcuello M, Duran-Sanchon S, Moreno L, Lozano J, Bujanda L, Castells A, et al.
Cancers (Basel)
. 2019 Oct;
11(10).
PMID: 31614785
Early detection of colorectal cancer (CRC) and its precancerous lesion, advanced adenomas (AA), is critical to improve CRC incidence and prognosis. Circulating microRNAs (miRNAs or miR) are promising non-invasive biomarkers...
7.
Marcuello M, Vymetalkova V, Neves R, Duran-Sanchon S, Vedeld H, Tham E, et al.
Mol Aspects Med
. 2019 Jun;
69:107-122.
PMID: 31189073
New non-invasive approaches that can complement and improve on current strategies for colorectal cancer (CRC) screening and management are urgently needed. A growing number of publications have documented that components...
8.
Vila-Navarro E, Duran-Sanchon S, Vila-Casadesus M, Moreira L, Gines A, Cuatrecasas M, et al.
Clin Transl Gastroenterol
. 2019 Apr;
10(4):e00029.
PMID: 31009404
Objectives: Pancreatic ductal adenocarcinoma (PDAC) presents the lowest survival rate of all cancers because only 6% of patients reach five-year survival. Alterations in the expression of several microRNAs (miRNAs) occur...
9.
Herreros-Villanueva M, Duran-Sanchon S, Martin A, Perez-Palacios R, Vila-Navarro E, Marcuello M, et al.
Clin Transl Gastroenterol
. 2019 Mar;
10(3):e00031.
PMID: 30913126
No abstract available.
10.
Herreros-Villanueva M, Duran-Sanchon S, Martin A, Perez-Palacios R, Vila-Navarro E, Marcuello M, et al.
Clin Transl Gastroenterol
. 2019 Feb;
10(1):e00003.
PMID: 30702491
Objectives: Specific microRNA (miRNA) signatures in biological fluids can facilitate earlier detection of the tumors being then minimally invasive diagnostic biomarkers. Circulating miRNAs have also emerged as promising diagnostic biomarkers...